What exactly did William Blair change in its DNTH analyst rating on March 16, 2026?

William Blair **maintained** an Outperform rating on March 16, 2026. The note reiterated confidence in Dianthus’ value inflection prospects but did not publish a new price target.

How should investors interpret the maintained Outperform in the DNTH analyst rating?

A maintained Outperform signals the analyst expects above-market returns relative to peers. Investors should combine this view with company milestones and the recent $625 million offering when sizing positions.

Did the March 16 DNTH analyst rating include a price target or model changes?

No. William Blair’s March 16, 2026 note did not disclose a new price target or explicit model revisions in the public summary. Investors should consult the full research note for details.

What is Meyka AI’s view after the William Blair DNTH analyst rating?

Meyka AI rates **DNTH with a grade of B+**. We see adequate runway after the March 10 offering and value potential from upcoming clinical catalysts, but coverage remains concentrated.

Analyst Ratings

William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026

ByHuzaifa Zahoor March 17, 2026March 17, 2026

William Blair maintained an Outperform rating on Dianthus Therapeutics, Inc. (DNTH) on March 16, 2026, and that decision defines today’s DNTH analyst rating landscape. William Blair reiterated confidence that the company “should see multiple value inflection for shares.” This note did not include a new price target, and the market reaction was modest, with a reported -0.83% (-$0.65) move following the update. Meyka AI’s real-time tracking flagged the reaffirmation as the primary analyst event for DNTH this week.